

## 2-Aminopyridinium (2-amino-pyridine)trichloronickelate(II)

Hoong-Kun Fun,<sup>a\*</sup> S. Franklin,<sup>b</sup> Samuel Robinson Jebas<sup>a‡</sup> and T. Balasubramanian<sup>b</sup>

<sup>a</sup>X-ray Crystallography Unit, School of Physics, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia, and <sup>b</sup>Department of Physics, National Institute of Technology, Tiruchirappalli 620 015, India  
Correspondence e-mail: hkfun@usm.my


Received 21 February 2008; accepted 28 February 2008

Key indicators: single-crystal X-ray study;  $T = 100$  K; mean  $\sigma(C-C) = 0.003 \text{ \AA}$ ;  $R$  factor = 0.035;  $wR$  factor = 0.080; data-to-parameter ratio = 38.5.

In the title compound,  $(C_5H_7N_2)[NiCl_3(C_5H_6N_2)]$ , the  $Ni^{II}$  atom is four-coordinated by three chloride anions and one N atom of a 2-aminopyridine ligand, forming a distorted tetrahedral coordination. In the crystal structure, cations and complex anions are linked into chains along the  $a$ ,  $b$  and  $c$  axes by  $N-H\cdots Cl$  hydrogen bonds, leading to the formation of a three-dimensional framework.

### Related literature

For related literature, see: Batsanov & Howard (2001); Bis & Zaworotko (2005); Chao *et al.* (1975); Corain *et al.* (1985); Jebas *et al.* (2006); Valdés-Martínez *et al.* (2001); Sletten & Kovacs (1993); Smith *et al.* (2000, 2001); Stibrany *et al.* (2004); Wei & Willett (1995); Windholz (1976).



### Experimental

#### Crystal data

$(C_5H_7N_2)[NiCl_3(C_5H_6N_2)]$

$M_r = 354.3$

Monoclinic,  $Cc$

$a = 12.9265 (1) \text{ \AA}$

$b = 8.0644 (1) \text{ \AA}$

$c = 13.9893 (1) \text{ \AA}$

$\beta = 106.163 (1)^\circ$

$V = 1400.67 (2) \text{ \AA}^3$

$Z = 4$

Mo  $K\alpha$  radiation

$\mu = 1.94 \text{ mm}^{-1}$

$T = 100.0 (1) \text{ K}$

$0.37 \times 0.08 \times 0.07 \text{ mm}$

#### Data collection

Bruker SMART APEXII CCD area-detector diffractometer with Oxford Cryosystems Cobra low-temperature attachment

Absorption correction: multi-scan (*SADABS*; Bruker, 2005)  
 $T_{\min} = 0.533$ ,  $T_{\max} = 0.876$

19539 measured reflections  
6427 independent reflections  
5088 reflections with  $I > 2\sigma(I)$   
 $R_{\text{int}} = 0.031$

#### Refinement

$R[F^2 > 2\sigma(F^2)] = 0.035$   
 $wR(F^2) = 0.079$   
 $S = 1.05$   
6427 reflections  
167 parameters  
2 restraints

H atoms treated by a mixture of independent and constrained refinement  
 $\Delta\rho_{\max} = 0.52 \text{ e \AA}^{-3}$   
 $\Delta\rho_{\min} = -0.64 \text{ e \AA}^{-3}$   
Absolute structure: Flack (1983), 1953 Friedel pairs  
Flack parameter: 0.065 (9)

**Table 1**  
Selected geometric parameters ( $\text{\AA}$ ,  $^\circ$ ).

|             |             |             |            |
|-------------|-------------|-------------|------------|
| Ni1—N1      | 2.0287 (17) | Ni1—Cl1     | 2.2665 (5) |
| Ni1—Cl2     | 2.2625 (6)  | Ni1—Cl3     | 2.2722 (6) |
| N1—Ni1—Cl2  | 114.10 (5)  | N1—Ni1—Cl3  | 104.63 (5) |
| N1—Ni1—Cl1  | 109.21 (5)  | Cl2—Ni1—Cl3 | 108.62 (2) |
| Cl2—Ni1—Cl1 | 107.77 (2)  | Cl1—Ni1—Cl3 | 112.60 (2) |

**Table 2**  
Hydrogen-bond geometry ( $\text{\AA}$ ,  $^\circ$ ).

| $D-H\cdots A$                      | $D-H$    | $H\cdots A$ | $D\cdots A$ | $D-H\cdots A$ |
|------------------------------------|----------|-------------|-------------|---------------|
| N3—H1N3 $\cdots$ Cl2 <sup>i</sup>  | 0.82 (3) | 2.81 (3)    | 3.380 (2)   | 128 (2)       |
| N2—H2B $\cdots$ Cl2                | 0.86     | 2.53        | 3.3475 (19) | 159           |
| N2—H2C $\cdots$ Cl1 <sup>ii</sup>  | 0.86     | 2.63        | 3.4866 (19) | 172           |
| N4—H4B $\cdots$ Cl3 <sup>i</sup>   | 0.86     | 2.36        | 3.197 (2)   | 165           |
| N4—H4C $\cdots$ Cl1 <sup>iii</sup> | 0.86     | 2.54        | 3.344 (2)   | 156           |

Symmetry codes: (i)  $x + \frac{1}{2}, -y + \frac{1}{2}, z + \frac{1}{2}$ ; (ii)  $x, -y + 1, z + \frac{1}{2}$ ; (iii)  $x, y - 1, z$ .

Data collection: *APEX2* (Bruker, 2005); cell refinement: *APEX2*; data reduction: *SAINT* (Bruker, 2005); program(s) used to solve structure: *SHELXTL* (Sheldrick, 2008); program(s) used to refine structure: *SHELXTL*; molecular graphics: *SHELXTL*; software used to prepare material for publication: *SHELXTL* and *PLATON* (Spek, 2003).

HKF and SRJ thank the Malaysian Government and Universiti Sains Malaysia for the Science Fund grant No. 305/PFIZIK/613312. SRJ thanks Universiti Sains Malaysia for the award a postdoctoral research fellowship.

Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: CI2566).

‡ Permanent address: Lecturer, Department of Physics, Karunya University, Karunya Nagar, Coimbatore 641 114, India.

## References

- Batsanov, A. S. & Howard, J. A. K. (2001). *Acta Cryst.* **E57**, m308–m309.
- Bis, J. A. & Zaworotko, M. J. (2005). *Cryst. Growth Des.* **5**, 1169–1179.
- Bruker (2005). *APEX2* (Version 1.27), *SAINT* (Version 7.12a) and *SADABS* (Version 2004/1). Bruker AXS Inc., Madison, Wisconsin, USA.
- Chao, M., Schemp, E. & Rosenstein, R. D. (1975). *Acta Cryst.* **B31**, 2922–2924.
- Corain, B., Longato, B., Angeletti, R. & Valle, G. (1985). *Inorg. Chim. Acta*, **104**, 15–18.
- Flack, H. D. (1983). *Acta Cryst.* **A39**, 876–881.
- Jebas, S. R., Balasubramanian, T. & Light, M. E. (2006). *Acta Cryst.* **E62**, m1818–m1819.
- Sheldrick, G. M. (2008). *Acta Cryst.* **A64**, 112–122.
- Sletten, J. & Kovacs, J. A. (1993). *J. Crystallogr. Spectrosc. Res.* **23**, 239.
- Smith, G., Bott, R. C. & Wermuth, U. D. (2000). *Acta Cryst.* **C56**, 1505–1506.
- Smith, M. C., Davies, S. C., Hughes, D. L. & Evans, D. J. (2001). *Acta Cryst.* **E57**, m509–m510.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Stibrany, R. T., Matturro, M. G., Zushma, S. & Patil, A. O. (2004). *Acta Cryst.* **E60**, m188–m189.
- Valdés-Martínez, J., Alstrum-Acevedo, J. H., Toscano, R. A., Espinosa-Pérez, G., Helfrich, B. A. & West, D. X. (2001). *Acta Cryst.* **E57**, m137–m139.
- Wei, M. & Willett, R. D. (1995). *Inorg. Chem.* **34**, 3780–3782.
- Windholz, M. (1976). *The Merck Index*, 9th ed. Rahway, New Jersey, USA: Merck & Co., Inc.